[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556317":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":47,"locations":56,"responsibleParty":96,"collaborators":99,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":103,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":18,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":59,"whyStopped":18,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"Aristotle University Of Thessaloniki","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Goserelin","EXPERIMENTAL","31 women with histologically confirmed endometriosis will receive goserelin acetate post-surgically.",[13],"Drug: Goserelin Acetate 3.6 mg inj, implant",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","31 women with histologically confirmed endometriosis will not receive pharmacological treatment post-surgically.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Goserelin Acetate 3.6 mg inj, implant","3.6 mg (1ml) administered subcutaneously once every month for 6 months (totally 6 injections)",[9],[26],"Zoladex",[28,32,35,37,39,41,44],{"name":29,"affiliation":30,"role":31},"Dimitrios A Anastasilakis, MD, PhDc","School of Medicine, Aristotle University of Thessaloniki","STUDY_DIRECTOR",{"name":33,"affiliation":34,"role":31},"Athina I Gkiomisi, MD, PhD","424 General Military Hospital, Thessaloniki, Greece",{"name":36,"affiliation":30,"role":31},"Dimitrios G Goulis, MD, PhD",{"name":38,"affiliation":30,"role":31},"Angelos Daniilidis, MD, PhD",{"name":40,"affiliation":34,"role":31},"Athanasios A Anastasilakis, MD, PhD",{"name":42,"affiliation":43,"role":31},"Chrysi Nalmpantidou, MD","\"G. Gennimatas\" General Hospital, Thessaloniki, Greece",{"name":45,"affiliation":30,"role":46},"Stergios A Polyzos, MD, PhD","PRINCIPAL_INVESTIGATOR",[48,53],{"name":45,"role":49,"phone":50,"phoneExt":51,"email":52},"CONTACT","2310999316","+30","spolyzos@auth.gr",{"name":29,"role":49,"phone":54,"phoneExt":51,"email":55},"6932238231","dimitanast@auth.gr",[57,79],{"facility":58,"status":59,"city":60,"state":18,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"1st Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki","RECRUITING","Thessaloniki","56403","Greece","GR",{"type":65,"coordinates":66},"Point",[67,68],22.93493,40.64072,{"lat":68,"lon":67},[71,74,77,78],{"name":36,"role":49,"phone":72,"phoneExt":51,"email":73},"2310233468","dgg@auth.gr",{"name":38,"role":49,"phone":75,"phoneExt":51,"email":76},"2310992843","angedan@auth.gr",{"name":36,"role":46,"phone":18,"phoneExt":18,"email":18},{"name":38,"role":46,"phone":18,"phoneExt":18,"email":18},{"facility":80,"status":59,"city":60,"state":18,"zip":81,"country":62,"countryCode":63,"cosmosGeoPoint":82,"geoPoint":84,"contacts":85},"424 General Military Hospital","56429",{"type":65,"coordinates":83},[67,68],{"lat":68,"lon":67},[86,90,91,92,94],{"name":87,"role":49,"phone":88,"phoneExt":51,"email":89},"Athanasios D Anastasilakis, MD, PhD","2310839900","a.anastasilakis@gmail.com",{"name":29,"role":49,"phone":54,"phoneExt":51,"email":55},{"name":87,"role":46,"phone":18,"phoneExt":18,"email":18},{"name":29,"role":93,"phone":18,"phoneExt":18,"email":18},"SUB_INVESTIGATOR",{"name":95,"role":46,"phone":18,"phoneExt":18,"email":18},"Athina I Gκiomisi, MD, PhD",{"type":46,"investigatorFullName":97,"investigatorTitle":98,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Stergios A Polyzos","Associate Professor of Pharmacology",[100],{"name":80,"class":6},"100556317","phase-4-effect-of-a-gnrh-analog-on-hepatic-steatosis-100556317",false,"NCT06523530","Effect of a GnRH Analog on Hepatic Steatosis","Effect of the Pharmacological Cessation of Menstruation With a GnRH Analog on Hepatic Steatosis in Women With Endometriosis","EndomMASLD","Inclusion Criteria:\n\n* women of reproductive age\n* diagnosis of endometriosis. The disease is suspected by patient's individual history (chronic pelvic pain, dyspareunia or\u002Fand dysmenorrhea) and the ultrasonographic imaging (chocolate cysts). The diagnosis is confirmed histologically, after laparoscopic surgical treatment and biopsy sampling, which will be interpreted by an independent blinded pathologist.\n* use of contraceptives, which is the first line treatment, is contraindicated or the patient does not consent to receive contraceptives, due to personal preferences.\n* written informed consent to participate to the study\n\nExclusion Criteria:\n\n* mean ethanol consumption \\>10 g\u002Fday\n* history of other chronic liver disease (e.g., viral hepatitis, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis and overlap syndromes, drug-induced liver injury, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency)\n* liver cirrhosis\n* any malignancy\n* chronic kidney disease\n* uncontrolled hypothyroidism or hyperthyroidism\n* severe sexual hormone disorders (congenital adrenaline hyperplasia, Down syndrome, Turner syndrome).\n* use of the following medications within a 12-month period before baseline, which are associated with drug-induced liver injury (DILI): interferon, tamoxifen, amiodarone, aloperidin, glucocorticoids, hormone replacement therapy, contraceptives, anabolic steroids, any medication against tuberculosis, epilepsy or viruses, methotrexate, parenteral nutrition\n* use of the following medications within a 12-month period before baseline, which are probably associated with improvement in hepatic steatosis: vitamin E, pioglitazone, insulin, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium- glucose co-transporter-2 inhibitors (SGLT-2i), orlistat, ursodeoxycholic acid\n* use of any GnRH agonist or antagonist within a 12-month period before baseline","FEMALE","18 Years","45 Years",{"count":113,"type":114},62,"ESTIMATED","INTERVENTIONAL",[117],"PHASE4","Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen. Gonadotropin-releasing hormone (GnRH) treatment in endometriosis is regarded as a model of pharmaceutical menopause. Thus, the effect of goserelin acetate, a GnRH analog that results in transient menopause, on hepatic steatosis and fibrosis will be evaluated in this study.",[120,121,122],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Nonalcoholic Fatty Liver","Endometriosis",[124,125,126,127,128,129,130,131,132,133,134,135,136],"endometriosis","goserelin acetate","hepatic fibrosis","MASLD","MASH","metabolic dysfunction-associated steatotic liver disease","metabolic dysfunction-associated steatohepatitis","NAFLD","NASH","nonalcoholic fatty liver disease","nonalcoholic steatohepatitis","treatment","menopause","2026-02-01",{"date":139,"type":140},"2026-02-03","ACTUAL",{"date":142,"type":140},"2024-11-26",{"date":144,"type":114},"2027-10",{"name":5,"class":6},2]